文献速递其他结缔组织病

他克莫司联合糖皮质激素初始治疗多发性肌炎/皮肌炎间质性肺炎的单臂临床试验

Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

这项多中心单臂52周临床试验评估了他克莫司联合糖皮质激素初始治疗PM/DM间质性肺炎患者(N=26)对短期死亡率的影响,52周生存率为88.0%(95%CI 67.3-96.0),严重不良事件发生率为44.0%,因历史对照仅16例而无法进行有意义的倾向评分匹配比较。

要点

  • 他克莫司联合糖皮质激素初始治疗PM/DM间质性肺炎52周生存率为88.0%(95%CI 67.3-96.0)。
  • 严重不良事件发生率为44.0%,包括4例机会性感染。
  • 因历史对照仅16例,无法进行有意义的比较分析。

核心结论

  • 他克莫司联合糖皮质激素初始治疗可能改善PM/DM间质性肺炎患者的短期死亡率,安全性可控。

研究设计与样本

  • 多中心、单臂、52周临床试验,纳入26例PM/DM间质性肺炎患者。
  • 他克莫司剂量0.075 mg/kg/day,调整目标全血谷浓度5-10 ng/ml;泼尼松龙0.6-1.0 mg/kg/day后缓慢减量。
  • 主要结局为总生存率;原计划采用倾向评分匹配与历史对照(初始单用糖皮质激素)比较,但历史对照仅16例(含1例死亡)而无法进行。

主要发现

  • 联合治疗52周生存率为88.0%(95%CI 67.3-96.0)。
  • 严重不良事件发生于11例患者(44.0%),包括4例机会性感染。
  • 安全性特征与他克莫司和高剂量糖皮质激素各自的已知安全性一致。

临床怎么用

  • 对于PM/DM间质性肺炎患者,可考虑他克莫司联合糖皮质激素作为初始治疗方案,但需注意监测严重不良事件包括机会性感染。

局限性

  • 单臂设计,无同期对照组。
  • 历史对照样本量小(仅16例),无法进行有意义的比较分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interstitial pneumonia is common and has high short-term mortality in patients with PM and DM despite glucocorticoid (GC) treatment. Retrospective studies suggested that the early use of immunosuppressive drugs with GCs might improve its short-term mortality. METHODS: A multicentre, single-arm, 52-week-long clinical trial was performed to test whether the initial combination treatment with tacrolimus (0.075 mg/kg/day, adjusted for the target whole-blood trough levels between 5 and 10 ng/ml) and GCs (0.6-1.0 mg/kg/day of prednisolone followed by a slow taper) improves short-term mortality of PM/DM-interstitial pneumonia patients. The primary outcome was overall survival. We originally intended to compare, by using propensity-score matching, the outcome data of clinical trial patients with that of historical control patients who were initially treated with GCs alone. RESULTS: The 52-week survival rate with the combination treatment (N = 26) was 88.0% (95% CI, 67.3, 96.0). Safety profiles of the combination treatment were consistent with those known for tacrolimus and high-dose GCs individually. Serious adverse events occurred in 11 patients (44.0%), which included four opportunistic infections. Only 16 patients, including only 1 deceased patient, were registered as historical controls, which precluded meaningful comparative analysis against the clinical trial patients. CONCLUSION: Our study provided findings which suggest that initial treatment with tacrolimus and GCs may improve short-term mortality of PM/DM-interstitial pneumonia patients with manageable safety profiles. This was the first prospective clinical investigation conducted according to the Good Clinical Practice Guideline of the International Conference on Harmonization for the treatment of this potentially life-threatening disease. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT00504348.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Takada K, Katada Y, Ito S, et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology (Oxford). 2020. PMID: 31539061. doi:10.1093/rheumatology/kez394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。